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This project focuses on evaluating the effects of nanoparticles on the cellular responses in human 
oral squamous cell carcinoma (HSC) cells during the administration of cisplatin. Cisplatin is an 
effective chemotherapeutic drug used to treat numerous forms of human cancer. It is, however, 
also highly susceptible to creating drug resistance in cancer cells. Restriction of the mobility of 
HSC cells reduces its ability to spread resistant cells throughout the body. In this study, we 
investigated the cellular mobility of HSC cells in the presence of a combination of cisplatin and 
nuclear-targeted gold nanocubes. The HSC cells were treated with cisplatin with and without 
nanocubes to study their effects on the mobility. Trends were assessed for changes in position and 
velocity over time. It was found that, the presence of nanoparticles alone restricts the displacement 
of the HSC cells. As an extension, the effects of nanoparticles on drug resistant HCS cells was 
studied. HSC cells were systematically treated with cisplatin to create cisplatin-resistant cell lines. 
The viability of these cell lines were then tested at different levels of drug resistance.  Furthermore, 
the effect of nuclear-targeted nanoparticles on bypassing drug resistance in cisplatin-resistant HSC 
cells were evaluated.  Trends amongst cell resistance and nanoparticle presence were assessed. 
Furthermore, the radius and surface charge were analyzed to understand characteristics that lead 
to optimal uptake. Additionally, the growth and changes in uptake experienced by cisplatin 





Gold nanoparticles provide an innovative method of drug delivery that can be created in many 
different shapes, sizes, and materials. Different physical characteristics of the nanoparticles lead 
to different applications. One such application is the use of nanoparticles in a variety aspects of 
biological systems--particularly as a nanomedicine-- with functions ranging from sensors to 
imaging to delivery vehicles1. An area where these methods are being tested is cancer treatment. 
These nanoparticles have been used to deliver chemotherapeutics or act as a treatment themselves 
when combined with thermal radiation2. The use of nanoparticles as a means of drug delivery has 
been studied in many ways1. This study investigates the application of gold nanoparticles in 
combination with cisplatin, a common chemotherapeutic, and their combined therapeutic 
application within human oral squamous cell carcinoma cells. The use of gold as a material for 
this study is due to its enhanced biological properties which can be combined with photothermic 
abilities3. The optimization of nanoparticles for increased uptake, specifically within human oral 
squamous cell carcinoma cells, is explored throughout this study. The trade-off between the 
binding of different ligands (molecules which are bound to the exterior of the nanoparticle) and 
the surface charge are assessed within this study to determine the optimal surface for increased 
nanoparticle uptake. While the binding of the ligands can reduce cytotoxicity and allows for 
localization, it also changes the nanoparticle’s surface charge. Different surface charges can lead 
to improper uptake if the charge is too negative. Moreover, the uptake of nanoparticles into 
cisplatin-resistant human oral squamous cell carcinoma cells is analyzed. The addition of the 
nanoparticles can allow for an increase in intracellular drug concentration due to a more effective 
uptake and faster drug release which can offset the effects of the resistivity. As photothermal 
therapy has previously been shown to be an effective treatment, this effectiveness is further 
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expanded upon for its application for cisplatin-resistant human oral squamous cell carcinoma cells. 
This study aims to increase the cellular uptake of gold nanoparticles in cisplatin resistant cells 
which in turn has the potential to overcome cisplatin resistance. 
 
Throughout this study, the nanoparticles were assessed in human oral squamous cell carcinoma 
cells and  in cisplatin resistant cells. Cisplatin is an anticancer drug that is effective due to its ability 
to enter the cell through multiple pathways by activating or silencing several genes. Once inside 
the cell, cisplatin effects DNA repair mechanisms leading to DNA damage and eventually 
apoptosis4. Cisplatin however has little selectivity for tumor versus normal tissue which limits the 
amount that can be used without detrimental side effects5. Dose limiting, in an effort to counteract 
the effects on normal tissue, leads to nephrotoxicity, myelosuppression, and chronic neurotoxicity 
and eventually an acquired resistance6. In many cases, cisplatin is combined with other therapies 
in attempts to overcome drug resistance and reduce toxicity7. Due to the complexity in which 
cisplatin interacts with the cell, the cisplatin resistance also arises from several separate and 
complex alternations8.  With so many varied factors combining to lead to resistance, it can be hard 
to combat this resistance and find effective ways to treat resistant cells which is the main source 
of failure in cisplatin treatment9. One of the changes that appears in the resistant cells is differences 
in the cell surface and changes in cell surface binding sites10. The main method of cellular 
accumulation of cisplatin is using transporters on the cell’s surface however resistant cells with 
different transporters cannot uptake the cisplatin. In this study, cisplatin was neither bound to the 
nanoparticle nor contained within the nanoparticle. Instead, they were both administered at the 
same time. The addition of the nanoparticles can allow for an increase in intracellular drug 
concentration due to a more effective uptake and faster drug release which can offset the effects 
of the resistivity. Nanoparticles are not moved across the cell membrane in the same way that 
 
 3 
cisplatin is; in fact, nanoparticles can uptake into the cell through several different pathways of 
their own11. This study aims to discover a way to increase the cellular uptake of nanoparticles in 
cisplatin resistant cells which in turn has the potential to overcome cisplatin resistance. 
 
Nanoparticles can be composed of different metal combinations such as gold, silver, and a gold-
silver alloy, yet gold nanoparticles have been the most thoroughly studied and have many more 
applications in biological systems3, 12. Gold nanoparticles have been shown to convert light into 
heat which allows them to be used in photothermal therapeutics in which a laser is used to excite 
the nanoparticle and in turn induce apoptosis, cell death, of the targeted cell. Many studies are 
focusing solely on the use of gold nanoparticles due to these properties and have seen success. 
Accomplished gold nanoparticle photothermal therapy has been shown in pilot therapies to 
completely eradicate cancer in over 50% of the mice treated and show no sign of reoccurrence 
even two weeks later13. Another study has moved to clinical trials following success using 
photothermal therapy on gold nanoshells to fully remove surface tumors14. A photothermal 
approach that induces hyperthermia in glioblastoma, an aggressive brain cancer, has even been 
clinically approved in Europe14. Throughout this study, gold nanoparticles were used due to their 
enhanced biological properties which decrease their inherent toxicity to cells combined with 
photothermic abilities. Nanoparticles on their own cannot, however, freely enter the cell but must 
instead be conjugated with different ligands to make the nanoparticles cell viable. By changing the 
ratios of these different ligands on the surface of the nanoparticles, their uptake can be optimized. 
The first part of this study was designed to find the optimal ratio to have optimal uptake for each 
given cell type. Though this process has been shown before, particularly for cancers that are not 
deep tissue, it has not been done thoroughly for human oral squamous cell carcinoma cells. One 
of the best ways to assist with the uptake of the nanoparticle is by conjugating it with different 
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ligands that increase its cell viability, reducing barriers to entry, and causing localization within 
the cell following uptake. This study determines the optimal ratio for uptake into human oral 
squamous cell carcinoma cells by conjugating nanoparticles in various ratios of ligands and 
assessing the differences in uptake through dark-field imaging. 
 
One of the ligands which can increase cell viability is polyethylene glycol, or PEG. In this study, 
the PEG ligand provides many different functions15.  One function is to create steric repulsion so 
that when the nanoparticle is in proximity to other nanoparticles, there is less risk of aggregation16. 
Other functions are to minimize the cytotoxicity of the nanoparticles and to stabilize the 
nanoparticles. In past experimentation, PEG has been shown to be effective at increasing the 
uptake in breast cancer17. This study aims to use PEG to replicate the properties seen in breast 
cancer within human oral squamous cell carcinoma. 
 
Reducing barriers to enter the cell stems from the nanoparticle’s ability to selectively bind to 
cancerous cells. In addition to PEG, ligand used was cysteine modified peptide with a specific 
amino acid chain, RGD (arginine-glycine-aspartic acid) sequence peptide )15. For the purposes of 
this study, the RGD ligand a targeting ligand which allows it to bind to cancer cells as it is used to 
target a common cancer marker that is expressed in the membrane of many different cancer lines 
including human oral squamous cell carcinoma. The binding to this membrane allows for the 
uptake of the nanoparticle into the cell by endocytosis. This also adds selectivity to the nanoparticle 
as it binds only to the cancerous cells while leaving the healthy cells alone. Consequentially, 




One of the most important aspects of nanoparticles is localization within the cell following uptake. 
The third ligand used in this study was a NLS (nuclear localization signaling) peptide  . This ligand 
targets the nucleus by binding to the nuclear transport receptors15. One important aspect that allows 
for increased responses to photothermal treatment is the accumulation of nanoparticles within one 
specific area of the cell. The accumulation around the nucleus is important as nucleus damage 
bypasses many other pathways to initiate apoptosis. This study analyzes the potential application 
of NLS as a means of accumulation within the cell. 
 
One of the main differences between the nanospheres and nanocubes is the surface charge. 
Different synthesis processes lead to different shapes occurring which also change the surface 
characteristics of the nanoparticle and in turn the surface charge. Nanoparticles with a negative 
surface are less likely to properly uptake18. These different ligands which are bound to the surface 
of the nanoparticle can have different effects on the charge associated with the surface and 
analyzed for a zeta potential, a measurement of surface charge. In nanoparticles, a zeta potential 
that lies between -10 and +10 mV is considered to be neutral while potentials that are greater than 
+30 mV or less than -30 mV are considered to be strongly cationic or anionic19. This associated 
charge can have a significant effect on the uptake of the nanoparticles along with their cytotoxicity. 
Throughout this study the zeta potential of the nanoparticles was analyzed to determine if the 
binding of different ligands cause a change in the surface charge. With an optimal goal to decrease 
the cytotoxicity of the nanoparticle to increase cellular uptake, how ligands effect surface charge 






Nanoparticles are materials that exist at the nanometer scale and can be engineered to have 
specialized compositions and functionalities20. Though these nanoparticles can have applications 
in many different fields, the emergence of the use of nanoparticles in biological and biomedical 
research has led to new forms of treatment and diagnostics. Nanoparticles may be synthesized 
from many different materials from liposomes to polymers to metals20. Some common metals used 
are gold or silver.  The emergence of gold nanoparticles as one of the front runners in terms of 
medical nanoparticles has stemmed from their low toxicity combined with their large variety of 
optical properties20. Gold nanoparticles have been used in diagnostics, photothermal therapy, and 
as drug carriers12. This study focuses on the optimization of gold nanoparticles in human oral 
squamous cell carcinoma cells, human oral squamous cell carcinoma, for their implementation of 
photothermal therapy.  
 
The use of nanoparticles as a means of local drug delivery has been explored for applications in 
cancer treatment. There are a variety of means by which a nanoparticle can be used to deliver 
drugs. One way is by synthesizing nanoparticles that experience structural changes such as the 
expansion of the shell given different pH environments2.  When a nanoparticle moves from a 
neutral to acidic region a common characteristic for cancer microenvironments, the shell can 
expand and release the drug that was encapsulated. Another mode by which nanoparticles can be 
used to deliver drugs is through different coatings on the outside of the nanoparticle. By coating, 
the outside of the nanoparticle with the drug the nanoparticle can then be controlled to reach the 
intended location either through magnetic or thermal properties21. Though pH-controlled release 
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of drugs has shown promise this study chose to focus on the coating of the nanoparticle and using 
the nanoparticle itself as a therapeutic.  
Despite the progress that has been made, one of the main struggles that face the future of 
nanoparticles as a means of cancer treatment is the optimization that is required for each type of 
cancer. As each different type of cancer cell differs not only structurally but also mechanistically, 
each nanoparticle must be specially tailored to the type of cell it is intended for. Though this study 
requires the optimization of the nanoparticle to be tailored to the specific type of cancer, the overall 
form of treatment, photothermal therapy, can be applied to cancers that are not in deep tissue. One 
of the biggest differences stems from the uptake of the nanoparticles into the cells which can be 
optimized to take advantage of the mechanisms already present in a specific cell type.  
 
The conjugation of different ligands to the exterior of nanoparticles helps to overcome the 
biological barrier and allows a foreign object into the cells while using the cell’s mechanisms to 
its advantage. Bellis has shown that in the past the use of RGD peptides can be used to enhance 
the cell biomaterial interaction22. The binding of RGD to the exterior of biomaterials has been 
shown to increase the adhesion of the biomaterial to the cell22. This predicts that the conjugation 
of RGD to the exterior of gold nanoparticles can lead to the nanoparticles being able to adhere to 
the cells. This study aims to show that the binding of RGD to the exterior of the nanoparticle allows 
for uptake into human oral squamous cell carcinoma cells despite it has not been previously shown 
that the binding of RGD to a nanoparticle leads to uptake of nanoparticles specifically within 




Though RGD allows the nanoparticle to bind to the cell, it does not decrease the cytotoxicity of 
the nanoparticle. Shenoy analyzes another substrate, polyethylene glycol, PEG, and its ability to 
increase cell-biomaterial interacions17. The conjugation of PEG has been shown to decrease 
cytotoxicity and as a result, allows for longer-term circulation of nanoparticles17. Not only does 
this decreased cytotoxicity enhance cellular uptake, but Panikkanvalappil has also shown that they 
can increase the uptake of the nanoparticles through receptor-mediated endocytosis23. This 
facilitated uptake takes advantage of receptors already present on the cells while also decreasing 
the chances of rejection. This study takes advantage of these shown properties by binding RGD to 
the exterior of the nanoparticle in combination with PEG. 
 
Furthermore, the use of nuclear localization signaling peptides, NLS, as a means of directing the 
nanoparticle to the nucleus once it has been up taken into the cell has also been examined23. By 
directing the nanoparticle to the nucleus, it helps to allow a faster localization of nanoparticles. 
This localization around the nucleus helps to increase a concentrated drug delivery, which 
oftentimes is focused on attacking the nucleus. This study takes the localization as driven by NLS 
and applies it to photothermal therapies. By bringing the nanoparticles together it allows them to 
have more of an effect when heating up than they would scattered throughout the cell. 
 
One of the main disadvantages of common chemotherapeutic treatments is the ability to develop 
resistance to the drug. One of the most common chemotherapeutics, cisplatin, attacks cancerous 
cells through multiple pathways at once24.  This allows it to be an effective treatment for several 
types of cancers, however, due to its multipronged approach, the changes a cell undergoes when 
developing resistance are not well understood. A pathway to overcoming resistance would allow 
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for more effective treatment of additional cancers. This study aims to provide that pathway by 
combining nanoparticle and cisplatin treatment simultaneously. 
 
This study looks at the applications of nanoparticles and their ability to help overcome cisplatin 
resistance. Optimization of the nanoparticles for human oral squamous cell carcinoma cells 
occurred using RGD, PEG, and NLS in different ratios to determine the ratio that leads to the 
maximum uptake. With the use of this optimized nanoparticle, the effect that cisplatin resistance 
has on the uptake of nanoparticles was studied. Understanding the difference in uptake from non-
resistant to resistant cells can help to lead to a better understanding of the effects that cisplatin 
resistance has on cell membrane receptors and transport. If this approach is proven to overcome 
cisplatin resistance, this approach may be able to be expanded to other cancers. This would be able 





Synthesis of Nanocubes 
The optimization of nanocubes was studied to find the optimal concentrations of various 
components necessary to form a nanocube conducive to uptake within the cell while also having 
proper light scattering properties. The cubes were created by initially combining H2O (40 mL) 
with cetyl trimethylammonium bromide, CTAB, (8000 µL, 0.1 M) and ascorbic acid (6000 µL, 
0.1 M). The final ingredient sodium borohydride (1 mM) was added in various volumes (2 µL, 5 
µL, 20 µL, 40 µL) which lead to changes in the overall size of the nanoparticle. The absorption 
spectra were obtained of each of the different solutions at various times after the addition of the 
sodium borohydride to study the rate of synthesis while also studying size changes. Following the 
completion of this study the nanocubes were made by combining H2O (40 mL), cetyl 
trimethylammonium bromide, CTAB, (8000 µL, 0.1 M), ascorbic acid (6000 µL,0 .1 M) and 
sodium borohydride (20 µL, 1 mM)25.  
 
Synthesis of Nanospheres 
The synthesis of nanospheres was done to form nanospheres of a viable size for imaging, trying to 
create nanospheres that allowed for optimal uptake but were not too small for accurate imaging. 
Initially Au (3.75 ml, 10 mM) was added into H2O (135 mL) and brought to a boil. Once the 
solution comes to a boil the trisodiumcitrate (5 mL ,35%) was added in causing the solution to 
complete a color change from a dark purple to a deep red wine color. The amount of 
trisodiumcitrate controls the overall size of the nanospheres with more trisodiumcitrate leading to 




Conjugation of Nanoparticles 
The nanoparticle itself does not readily uptake into the cells and must therefore be conjugated with 
different ligands to help achieve uptake. One ligand is Polyethylene glycol (PEG), an ethyl 
functionalized polymer that allows binding by forming a covalent bond to create a thiol bond which 
comes in many different lengths and serves to protect the molecule and make it cell viable. Another 
ligand that was used was arginine-glycine-aspartate, RGD, a tri amino acid sequence adhesive 
peptide that helps to provide a bio-tolerant surface throughout endocytosis. Additionally, it helps 
to bind to the targeted proteins while also binding to the nanoparticles in controlled densities. The 
third ligand is a nuclear localization sequence, NLS, is an amino acid sequence which can be used 
to assist with uptake and endocytosis by binding to the nuclear membrane and serving as a nuclear 
transport facilitator. Nanospheres and nanocubes were bound with vary percentages (100% PEG, 
50% PEG/ 50% RGD, and 50% PEG/ 30% RGD/ 20% NLS) of the three ligands to study the 
varying effect on uptake. These nanoparticles were conjugated by exposing the particles to the 
correct about of ligand necessary given the size, shape, and concentration of particles. The 
nanoparticles are then allowed 24 hours for complete conjugation before use in any study26. 
  
Cell Preparation 
For different experiments either breast cancer, MDA-MB-231 or human oral squamous cell 
carcinoma, HSC-3 cell lines were prepared. Both non-resistant and cisplatin resistant cells were 
cultured. The cells were first split and then later injected with the different nanoparticle solution. 
The cells were taken from a plate on which they were previously split. The media was pulled from 
the plate. The plate was then rinsed with PBS to stabilize pH and remove dead cells. The PBS was 
then removed. Trypsin (1.5 mL) was then added to the plate to release the cells from the plate. The 
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plate was then incubated (5-7 min). More new media (1.5 mL) was added to the plates once the 
cells had released fully to neutralize the remaining trypsin. The entire solution was then removed 
and placed into a vial and centrifuged (5 min 1500 RPM). The old media is discarded leaving the 
pellet. New media is added to the vial. Media (10 mL) is added to a new plate. Some of the new 
pellet and media solution is added to the plate for later cell line splits27. For experiments involving 
cisplatin resistant cells, 24 hours after initial splitting of cells cisplatin (20 uL, 5.4 uM) was added 
to the plate. The media was replaced 24 hours later to allow for the growth of the resistant cells. 
Cells that were more resistant to the cisplatin required longer incubation period so after two rounds 
of treatment the incubation period before exposure to cisplatin was increased to 48 hours. For 
experiments involving dark field imagining, cover slips for every reaction, a control and the three 
different solutions with various ligands, were each placed into a well plate. Some of the media and 
pellet solution was added into each well to dilute the cells to the proper level. Cells were then 
incubated for 24 hours before being injected with the proper ligand solution. Cells were then 
incubated for 24 hours. This was repeated for both cell lines with all solutions using both 
nanocubes and nanospheres.  
 
Cell Analysis using Dark Field Imaging 
Dark field imagining allows for images of the cells to be taken by using the light scattering 
properties of the nanoparticles. Images of the cells were taken once the cells had undergone 
nanoparticle uptake for 24 hours. The cover slips from the well plate were then used to create slides 
for each of the different runs. If the run has nanoparticles, all except the control, the slides are first 
rinsed with PBS and then added to media again. The coverslip was removed from the well and 
placed on the slide plate. Media (650 µL) was then added to the slide plate. Slide was placed into 
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the incubator until ready to measure it under the microscope. The slide was then analyzed using a 
Leica Infinity 2 microscope26.  
 
Image Analysis for Optimization of Nanoparticles via Uptake Studies 
The images obtained from each run were then analyzed in ImageJ Fiji to calculate the intensity 
which can be used to determine the uptake of the nanoparticles into the cells. The images from 
five different sections of the field were chose and analyzed. The intensity is proportional to the 
amount of uptake that occurred as more uptake leads to more scattering and in turn a more intense 
response. The image was upload into ImageJ and converted from a 32-bit RGB image to a 16-bit 
grayscale image and in turn to a binary reading. This binary reading allows for the intensity of 
individual cells to be tracked. For each run the average intensities for each cell were then used to 
find an average intensity for the uptake for a given run.  
 
Cell Analysis and Drug Introduction 
Both HSC-3 and MDA-MB-231 cells obtained from ATCC were cultured and analyzed for cell 
movement. After exposure to nanoparticles, the cells were then monitored to study the movement 
both in the case of exposure to Cisplatin and without Cisplatin. Each well was place into an 
Olympus IX70 Inverted Microscope to allow for constant pictures to be obtained of the movement. 
In the microscope the conditions were carefully maintained throughout the whole run time. The 
temperature was maintained by running water around the well at a constant temperature. The 
environment was also maintained by the constant presence in both flow and pressure of carbon 
dioxide. Cisplatin of various concentrations were added to the cells. An image of the cells was 
then obtained every two minutes with a Nikon camera. These images were set to automatically be 
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captured to ensure constant and consistent timing. This allowed for a real time analysis of the 
Cisplatin interaction with the cells. 
  
Movement Analysis of Cisplatin Exposed Cells 
The images that were obtained from each run were then compiled into a video. This video had 
each photo as a new frame allowing for the position and velocity to be tracked over time. The 
video was then uploaded into ImageJ for processing. ImageJ was used to track the movement of 
individual cells across the entirety of the time. Every individual cell was followed throughout the 
duration of the video. Once the single cell had been tracked the track was ended. This was repeated 
with the other cells visible in the frame, adding a new track for each new cell. The data collected 
was then added into Excel. This data was used to plot the position of each cell over time. The 
position of each cell was reoriented to show all the position paths at the same time. The position 
data was then used to generate the velocity for each of the cells. The average velocity was then 
calculated for each different exposure to Cisplatin 
 
Zeta Potential and Hydro Dynamic Light Scattering 
Zeta potential and hydro dynamic light scattering testing was done on the conjugated nanoparticles 
to determine the surface charges along with the size of the nanoparticles. This analysis shows the 
changes that the different conjugations had on both the overall size of the particle and the surface 
charge which can lead to changes in uptake. The conjugated nanoparticles were centrifuged lightly. 
After centrifuge the nanoparticles (500 uL) were added to the DIP Cell. The DIP Cell was inserted 
into the Malvern Zetasizer Nano Series and the sample was run. The zeta potential was then 
graphed versus the number of times it occurred. From this an average zeta potential was calculated. 
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Each different conjugation was run in triplicate28. The conjugated nanoparticles were also run in a 
Wyatt DynaPro NanoStar to determine the radius via dynamic light scattering. The nanoparticles 
(200 uL) were added into the cuvette and placed into the NanoStar and run at constant temperature 
(25 C). The average radius was then graphed versus intensity for different conjugations. Each 
different conjugation was run in triplicate29.  
 
Cell Analysis via Cell Viability 
Cell analysis was performed via a Vi-CELL cell viability assay. The viability assays were used to 
determine the survival rate of the HSC-3 cells under a variety of conditions to determine whether 
the nanoparticles themselves had an inherent toxicity of the cells. The viability was tested for each 
of the cell lines. The viability was run for just the cell, the cell in the presence of cisplatin, the cell 




Results and Discussion 
 
The physical characteristics of the nanoparticles used lead to light scattering, which can be 
observed through different forms of microscopy. Analyzing nanoparticles through microscopy 
allows for easy assessment to assure that the intended processes are occurring, and that the 
nanoparticles are being delivered to the cells. Throughout this study, the imaging properties of the 
nanoparticles were used to quantify the cellular uptake. The light-scattering properties of the gold 
nanoparticles were combined with dark-field imaging to get an accurate portrayal of uptake and 
localization with HSC-3 cells in this study.  
 
Analysis of the effect of Sodium Borohydride on Growth of Nanocubes 
The creation of nanocubes was studied to find the correct concentrations of various ingredients 
necessary to form an effective nanocube. The cubes were created by initially adding H2O (40 mL) 
with cetyl trimethylammonium bromide, CTAB, (8000 µL,0.1 M). Next ascorbic acid (6000 µL, 
0.1 M) was added. The final ingredient sodium borohydride (1 mM) was added in various volumes 
(2 µL, 5 µL, 20 µL, 40 µL). The absorption spectra were obtained of each of the different solutions 
at various times after the addition of the sodium borohydride (NaBH4).  
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This impact of the amount of 
NaBH4 on the growth rate of 
the nanoparticle is visibile only 
in the solution with 2 uL 
(figure 1). This is because in 
the other solutions the 
concentration of the NaBH4 is 
so high that the reaction runs 
almost immediately to 
completion. In the 5 µL NaBH4 
solution there is a visible shift 
between the 20-minute solution and the others. This shows that after 20 minutes the solution was 
still not at completion. This comparison over time reinforces the fact that the nanocubes should 
not be immediately used if created with a low volume of NaBH4 while also showing that the 









Figure 1. Wavelength comparison of cubes created with various concentrations of 





Synthesis of Nanocubes 
 
Figure 2. Image of the nanocubes used in the experiment  
along with the correct scale. 
 
Uptake of Nanocubes in MDA and HSC 
 
Figure 3. Uptake of Nanocubes bound with different ratio of ligands in HSC-3 and MDA-MB-231 






Figure 4. Uptake of Nanospheres bound with different ratio of ligands in HSC-3 and MDA-MB-231 
Absolute Intensity Comparison 
The absolute intensity of the uptake was measured for both cell lines, MDA-MB-231 and HSC-3, 
with particles bound with PEG, PEG and RGD, and PEG RGD and NLS (figure 6). The intensities 
were measured using ImageJ. The uptake images were converted to grayscale images and the 
brightness from the cells were then measured. The cells were exposed to both the nanocube and 
the nanosphere shapes to assess if the trend were shape specific. In both cell lines, there was a 
similar trend for the intensities of the cubes. For both the PEG and RGD bound nanocubes 
experience the most uptake while both the PEG RGD NLS bound along with the only PEG bound 
experienced much less uptake. Both cell lines also experienced similar trends with the ligand 




bound spheres. The PEG only bound particles experienced the least uptake while the PED RGD 
and NLS bound particles received the most uptake. The data was analyzed using ANOVA. The F 
value was 312.73 with a p value that is less than .00001 indicating that the results are significant 
at p<.05. The difference in the two trends is due to a change in the surface charge associated with 
a change in surface area and number of ligands which can bind.  
 
Understanding the best ligands to bind to different nanoparticles and understanding how a specific 
cell line will react to the change in ligands allows for a more specific and targeted nanoparticle to 
be used on the cell line. By varying the type of nanoparticle that was used the uptake intensity that 
was experienced was drastically different. This is due to a change in surface charge based on how 
it is made and may be explained by the CTAB potential. The nanocubes were made with CTAB, 
which can cause a cationic surface on the nanocubes. Ideally nanoparticles would have no surface 
charge as a surface charge can lead to cytotoxicity. The difference in the surface charge of the 
nanocubes and nanospheres could explain the difference in the uptake trends. This charge could 
have led to additional matrix effects, which caused the PEG RGD and NLS bound nanocubes to 
have less uptake which is not what was expected. The nanospheres on the other hand increased the 
uptake with the addition of a ligand. This is more like what was expected. Though the general 
trends were the same the HSC-3 cells experienced more uptake. This was analyzed through a one-
tailed to test to determine the p value of .0038 which indicates that the increase is statistically 
significant. Though the nanocubes bound with PEG and RGD had the most uptake the fact that 




Movement of HSC-3 Cells
 
Figure 6. 15 cells were track for each study. A: HSC cells with nanoparticles without the cisplatin position. B: HSC cells with 
nanoparticles and cisplatin at a low concentration position. C: HSC cells with nanoparticles and cisplatin at a low concentration 
position. D: HSC cells without nanoparticles and with a low concentration of cisplatin position. E: HSC cells without nanoparticles 
or cisplatin position. F: HSC cells without nanoparticles with a low concentration of cisplatin position. The position of all the 







Not only were still images of the HSC-3 cells with nanoparticles obtained, but also live videos 
were obtained which allowed the movement of the cells to be studied. This analysis allowed for 
an assessment on the impact that the addition of nanoparticles has on metastasis. This additional 
functionalization allows the nanoparticles to be utilized beyond a curative treatment, attacking the 
present illness, but also preventative, reducing the chance of the cancer spreading. The HSC with 
nanoparticles in the presence of a high concentration moved significantly more than the HSC 
without the cisplatin with a p value of .0021 (figure 7B). This indicates that the presence of 
cisplatin increases the mobility of the HSC cells. The HSC with the nanoparticles and a low 
concentration of cisplatin moved similar distances as compared to the HSC with nanoparticles 
without cisplatin (figure 7C). While the mobility was increased, it was not done to the same degree 
as it was in the higher concentration with a p value of .037. This indicates that the higher the 
concentration of cisplatin the more the mobility is increased. The HSC without the nanoparticles 
or the cisplatin moved slightly more than the HSC with the nanoparticles (figure 7E). This appears 
to indicate that the addition of nanoparticles decreases the mobility of the cells. This reaffirms the 
belief that nanoparticles used as a means of treatment have the potential to reduce metastasis on 
their own. 

























 1 0.563 1.94 0.925 2.73 1.46 1.57 
 2 0.441 1.60 0.925 2.73 0.753 1.43 
 3 0.319 1.26 0.925 2.73 0.346 0.876 
 4 0.197 0.918 0.925 2.73 0.124 0.765 
Avg.   0.380 1.43 0.925 2.73 0.671 1.16 
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The average velocity of the different runs was analyzed every hour (table 1). When not in the 
presence of drugs the velocity was steady throughout the duration. The HSC-3 cells with the 
nanoparticles had a much lower velocity than that of the HSC-3 cells without the nanoparticles as 
concluded by a t test with a p value of .025. This indicates that the presence of the nanoparticles 
along decreases the velocity as seen by the decreased movement (figure 7). The HSC cells with 
nanoparticles with the higher concentration experienced a much lower average velocity than that 
of the lower concentration. Both runs however experienced an over 50% decrease in velocity by 
the end of 4 hours. The average velocity for the low concentration was however over 3 times as 
high as that of the high concentration. A similar pattern was observed in the HSC cells without the 
nanoparticles. The average velocity for the low concentration was twice as high as   that of the 
high concentration. This indicates that the increase in the concentration of the cisplatin leads to a 
greater decrease in velocity. 
 
Cell Viability Analysis 
Table 2. The cell viability was run for every line for the cell alone, in the presence of cisplatin, in the presence of nanoparticles, 
and in the presence of cisplatin and nanoparticles. 
 
The viability of the cells in different combinations of cisplatin and nanoparticles leads to 
different results in cell viability (table 2). The viability is indicative of the response to the 





Cell in the Presence 
of Cisplatin 
Cell in the Presence 
of Nanoparticles 
Cell in the Presence of 
Nanoparticles and Cisplatin 
Control 0 doses 100.00 69.78 133.81 68.73 
Round 4 1 dose 100.00 85.85 148.20 126.01 
Round 3-1 2 doses 100.00 79.02 108.60 70.64 
Round 3-2 2 doses 100.00 78.47 88.43 81.61 
Round 2-1 3 doses 100.00 84.05 88.95 89.39 
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of cisplatin that were used to create the cell line. These trends were then compared to the control 
which had no prior exposure to cisplatin. Though not enough data was obtained preliminary data 
was used to draw potential conclusions.  
 
Figure 7. The cell viability was measured for the cell in the presence of cisplatin alone over all cell lines. The control, with no 
doses of cisplatin is shown at 0. The cell with one treatment of cisplatin is show at one. The cells with two separate doses of 
cisplatin are shown at two. The cell with three doses of cisplatin are shown at 3.  
 
Figure 8. The cell viability was measured for the cell in the presence of cisplatin and treated with nanoparticles. The control, 
with no doses of cisplatin is shown at 0. The cell with one treatment of cisplatin is show at one. The cells with two separate doses 
of cisplatin are shown at two. The cell with three doses of cisplatin are shown at 3. 
Cell resistivity due to previous doses of cisplatin lead to a much higher cell viability than that of 
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of cisplatin to produce resistance had the highest cell viability and in turn the highest resistivity. 
The cell viability can be seen to remain steady the more that the cell was exposed to cisplatin. 
This is indicative of prolonged and repeated exposure to cisplatin reducing the resistance. 
However, the control with no previous exposure had the lowest cell viability. It is projected that 
the amount of prior exposure to cisplatin does not dramatically change the resistivity. A different 
pattern can be seen in the presence of nanoparticles (figure 9). Though the cell viability is 
drastically higher for those treated with nanoparticles, the cell viability also decreases rapidly. It 
can even be seen that the cell viability of the control is only marginally lower than that of the 
cells treated with cisplatin two times previously. This indicates that the presence of nanoparticles 
can cause a dramatic change in the cell viability while the trend remains the same whether 
nanoparticles are present or not. 
 
Figure 9. The viability of the cells that were treated with cisplatin were compared to those that were also treated with 
nanoparticles. The control, with no doses of cisplatin is shown at 0. The cell with one treatment of cisplatin is show at one. The 
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Figure 10. The cell viability of cells in the presence of nanoparticles was compared to those in the presence of nanoparticles and 
cisplatin. The control, with no doses of cisplatin is shown at 0. The cell with one treatment of cisplatin is show at one. The cells 
with two separate doses of cisplatin are shown at two. The cell with three doses of cisplatin are shown at 3. 
The presence of nanoparticles is preliminarily believed to not have an effect on the cell viability 
of the control cells (figure 10). This indicates that the nanoparticle has a low toxicity on the cell. 
The only toxicity and harm to the cell as a result is coming from the presence of cisplatin and not 
from the nanoparticle itself. This is an encouraging as if nanoparticles pose no innate harm or 
distress to the cell, they will not cause any harm or distress to a normal healthy cell which could 
allow them to be used as a form of treatment. It is shown that the presence of nanoparticles leads 
to a higher viability, though that initial increase is lessened over time. The difference between 
those cells in the presence of nanoparticles which were treated with cisplatin is also lessened 
over time (figure 11). The fewer the number of prior doses of cisplatin the greater the difference 
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Figure 11. Each of the cells were treated with nanoparticles and the cell viability was run. The control, with no doses of cisplatin 
is shown at 0. The cell with one treatment of cisplatin is show at one. The cells with two separate doses of cisplatin are shown at 
two. The cell with three doses of cisplatin are shown at 3.  
 
 
Figure 12. The uptake of nanoparticles by both a resistant cell and a nonresistant cell was analyzed by dark field imaging. A: 
The uptake of nanoparticles in cisplatin resistant HSC cells that received 3 separate doses of cisplatin. B: The uptake of 
nanoparticles in normal non-treated HSC cells. 
When treated with nanoparticles but not cisplatin the cell viability initially increases (figure 12). 
With more than one prior does of cisplatin, however the cell viability decreases drastically. This 
could be due to a lesser uptake of nanoparticles by cells with more previous doses of cisplatin 
(figure 13). The more doses of cisplatin that a cell received the more that it changed the cell 
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times as long as a normal cell to reach the same level of confluency. The shape of the treated 
cells also started to differ slightly from that of normal cells. These changes indicate that the 
growth pattern, along with the structure of the cells is impacted by treatment with cisplatin. The 
difference in the structure could lead to differences on the surface which impact nanoparticle 
uptake. It is possible that this lower uptake is the cause of the decrease in cell viability as the 
number of previous doses of cisplatin increases. The only cell with higher viability is that which 
was only treated with cisplatin once prior and had a much faster growth rate and fewer visible 
differences. If the nanoparticle was to be adopted to allow for better uptake into the more dosed 
cells it could dramatically increase the cell viability as seen in the cell with only one prior dose 
of cisplatin (figure 10). The connection between nanoparticle uptake and the cell viability is 
strong (figure 11). With a greater uptake in nanoparticles the cells which received more prior 
doses of cisplatin would in turn have higher viability.  
 
Figure 13. Two cells which received the same number of prior doses of cisplatin received different amounts of cisplatin each 
time. 
For the two cells which underwent the same number of previous doses of cisplatin, but different 
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there was no changed based on the dosage (figure 14). There was however a significant 
difference when it came to the cell viability in the presence of nanoparticles and in the presence 
of nanoparticles and cisplatin. The cell which received an overall larger amount of cisplatin 
overtime have a lower cell viability in the presence of nanoparticles. This indicates that the 
uptake of the nanoparticles was not as successful as it was for the lower overall amount of 
cisplatin. This reaffirms the earlier discussed idea that as the amount of prior cisplatin exposure 
increases the uptake of the nanoparticle decreases. The cell with the overall larger amount of 
cisplatin over time however has a higher cell viability in the presence of nanoparticles and 
cisplatin. This indicates that the larger the overall exposure to cisplatin the higher the resistivity. 
A greater uptake of nanoparticles however could lead to a lower cell viability.  
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Zeta Potential Analysis 
The zeta potential was determined 
for each different conjugation of the 
conjugations of nanoparticles. In the 
case of the 2,000 g/mol PEG 
conjugations both the 100% PEG 
and the 50% PEG 50% RGD there 
appears to be a higher standard 
deviation in the zeta potential as it 
ranges more wildly from -100 to 100 
mV.  The 50% PEG/ 30% RDG/ 
20% NLS however produced the 
nice expected gaussian curve with an 
average zeta potential of 40.3 mV 
(figure 15). While the PEG and 
PEG/RGD conjugations are both 
well within the potential range for 
neutral nanoparticles, the 
PEG/RGD/NLS conjugation is just 
outside of the range of neutrality 
indicating that it has cation charge 
on its surface. In this case it appears as though the introduction of RGD slightly increased the zeta 
Figure 14. A: The zeta potential for the 100% PEG conjugated nanoparticle 
was calculated. The average was found to be 2.03 mV. B: The zeta potential 
for the 50% PEG/50%  RGD conjugated nanoparticle was calculated.  The 
average was found to be 7.75 mV. C: The zeta potential for the 50% PEG 
/30% RGD/ 20% NLS conjugated nanoparticle was calculated.  The average 
was found to be 40.3 mV. 
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potential while the introduction of NLS 
vastly increased the zeta potential. The 
zeta potential graphs for the 5,000 
g/mol PEG conjugations all more 
closely resembled a gaussian curve 
than that of the 2,000 g/mol PEG 
conjugations. Similarly, however the 
curve of the PEG/RGD/NLS is the 
most gaussian while both the PEG and 
PEG/RGD experienced some slight 
shifts. The 100% PEG was found to 
have an average zeta potential of 35.4 
mV (figure 16). This is statistically 
significantly higher than that of the 
2,000 g/mol conjugated 100% PEG 
according to an ANOVA test giving a 
p value of .00087. The zeta potential 
for the 50% PEG/ 50% RGD was 
found to be 30.9 mV (figure 2). This is also significantly higher than that of the 2,000 g/mol PEG. 
This is however a decrease from the 100% PEG indicating that the presence of RGD decreases the 
overall zeta potential. The zeta potential of the 50% PEG/30% RGD/ 20% NLS was found to be 
37.3 mV (figure 16). This is a slight increase from that of the other 5,000 g/mol PEG conjugations. 
Figure 15. A: The zeta potential for the 100% PEG conjugated 
nanoparticle was calculated. The average was found to be 35.4 mV. B: 
The zeta potential for the 50% PEG/50% RGD conjugated nanoparticle 
was calculated. The average was found to be 30.9 mV. C: The zeta 
potential for the 50% PEG /30% RGD/ 20% NLS conjugated 
nanoparticle was calculated. The average was found to be 37.3 mV. 
 
 32 
This however is a slight decrease from the 
similarly conjugated 2,000 g/mol which had a 
zeta potential of 40.3 mV for the 50% 
PEG/30% RGD/ 20% NLS conjugation. 
When looking at zeta potentials for the 10,000 
g/mol conjugations similar trends were seen. 
All three of these zeta potential measurements 
displayed the expected gaussian curves. The 
zeta potential for the 100% PEG was 6.13 mV 
(figure 17). The zeta potential for the 50% 
PEG 50% RGD was found to be 4.32 mV.  
This shows the same decrease that was 
present in the 5,000 g/mol conjugation when 
RDG was added as a ligand. In the case of the 
50% PEG/30% RGD/ 20% NLS conjugation 
the zeta potential was found to be 6.25 mV. 
This is again the same trend as was seen in the 
5,000 g/mol conjugations. All these zeta 
potentials fall into the neutral range for nanoparticles and in turn have no significant charge 
associated with the surface.  
 
 
Figure 16. A: The zeta potential for the 100% PEG conjugated 
nanoparticle was calculated. The average was found to be 6.13  mV. 
B: The zeta potential for the 50% PEG/50%  RGD conjugated 
nanoparticle was calculated.  The average was found to be 4.32 mV. 
C:  The zeta potential for the 50% PEG /30% RGD/ 20% NLS 
conjugated nanoparticle was calculated.  The average was found to 
be 6.25 mV. 
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Dynamic Light Scattering for Analysis of the Radius of the Nanoparticles
 
Figure 17. The radius of the individual nanoparticles was measured using dynamic light scattering. A: The radius was measure 
10 separate times for the 100% PEG conjugated nanoparticles. The normalized intensity was also measured. B: The relative 
intensities of each measured radius for the 100% PEG. C: The radius was measure 10 separate times for the 50% PEG/50% RGD 
conjugated nanoparticles. The normalized intensity was also measured. D: The relative intensities of each measured radius for the 
50% PEG/50% RGD. E: The radius was measure 10 separate times for the 50% PEG/30% RGD/20%NLS conjugated 
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nanoparticles. The normalized intensity was also measured. F: The relative intensities of each measured radius for the 50% 
PEG/30% RGD/20%NLS.  
For each of the different conjugations the average radius was plotted along with the relative 
intensities for each radius (figure 18). In each of the different conjugations there is a small intensity 
at a smaller radius along with a much larger intensity at a larger radius. The smaller radius could 
indicate nanoparticles that were not fully covered by ligands. In the case of the 100% PEG 
conjugated nanoparticles the radius was found to be 25.02 nm. When the conjugation was changed 
to 50% PEG/ 50% RGD the average radius increased to 26.87 nm and when changed to 50% 
PEG/30% RGD/20%NLS the average radius was 26.138 nm. The addition of RGD causes a slight 
increase in the average radius. The average radius in the presence of both RGD and NLS was 
slightly larger than that of only PEG but still not as large as the 50% PEG/ 50% RGD conjugation. 
This indicates that it is the RGD that is the cause of the increase in radius. When the amount of 
RGD conjugated decreases, as it does when the percent of RGD drops from 50% to 30%, it leads 




Figure 18 . The radius of the individual nanoparticles was measured by dynamic light scattering. A: The radius was measure 10 
separate times for the 100% PEG conjugated nanoparticles. The normalized intensity was also measured. B: The relative intensities 
of each measured radius for the 100% PEG. C: The radius was measure 10 separate times for the 50% PEG/50% RGD conjugated 
nanoparticles. The normalized intensity was also measured. D: The relative intensities of each measured radius for the 50% 
PEG/50% RGD. E: The radius was measure 10 separate times for the 50% PEG/30% RGD/20%NLS conjugated nanoparticles. 




In the 5,000 g/mol a similar pattern was seen in the distribution of the of radii. Again, there is a 
less intense measurement with a smaller radius along with a more intense measurement at a higher 
radius. When looking at the 5,000 g/mol conjugations the 100% PEG conjugation had an average 
radius of 28.74 nm. This is significantly larger than that of the 2,000 g/mol conjugation indicating 
that the increase in chain length leads to an increase in overall size. When changing the conjugation 
to 50%PEG/ 50% RGD the radius dropped to 23.54 nm while the 50% PEG/30% RGD/20%NLS 
conjugation had an average radius of 23.69 nm. This indicates that the presence of RGD decreases 
the radius. When there is less of a percentage of RGD as there is in the 50% PEG/30% 




Figure 19. The radius of the individual nanoparticles was measured by dynamic light scattering. A: The radius was measure 10 
separate times for the 100% PEG conjugated nanoparticles. The normalized intensity was also measured. B: The relative intensities 
of each measured radius for the 100% PEG. C: The radius was measure 10 separate times for the 50% PEG/50% RGD conjugated 
nanoparticles. The normalized intensity was also measured. D: The relative intensities of each measured radius for the 50% 
PEG/50% RGD. E: The radius was measure 10 separate times for the 50% PEG/30% RGD/20%NLS conjugated nanoparticles. 





As with the 2,000 and 5,000 g/mol conjugations there are two separate intensities, a smaller one 
with a lower radius and a more intense one with a higher radius. The 100% PEG conjugation for 
the 10,000 g/mol had an average radius of 36.16 nm. This is higher than that of the 2,000 g/mol 
and the 5,000 g/mol. This indicates that increasing the chain length increases the overall radius. 
The 50% PEG/ 50% RGD conjugation has an average radius of 33.92 nm. This reaffirms the trend 
observed in the 5,000 g/mol that the presence of RGD decreases the overall average radius. When 
the conjugation changes to 50%PEG/30%RGD/20%NLS the radius increased back up to 35.67 
nm. This again reaffirms the trend observed in the 5,000 g/mol that by decreasing the RGD 
percentage the radius increased.  
 
 
Figure 20. Uptake of 2,000 g/mol conjugated nanoparticles: A: HSC cells with nanoparticles with 100% PEG at a 5x 
magnification. B: HSC cells with nanoparticles with 100% PEG at a 20x magnification. C: HSC cells with nanoparticles with 50% 
PEG/50% RGD at a 5x magnification. D: HSC cells with nanoparticles with 50% PEG/50%RGD at a 20x magnification. E: HSC 
cells with nanoparticles with 50% PEG/30%RGD/20%NLS at a 5x magnification. F: HSC cells with nanoparticles with 50% 




Figure 21. Uptake of 5,000 g/mol conjugated nanoparticles: A: HSC cells with nanoparticles with 100% PEG at a 5x 
magnification. B: HSC cells with nanoparticles with 100% PEG at a 20x magnification. C: HSC cells with nanoparticles with 
50% PEG/50% RGD at a 5x magnification. D: HSC cells with nanoparticles with 50% PEG/50%RGD at a 20x magnification. E: 
HSC cells with nanoparticles with 50% PEG/30%RGD/20%NLS at a 5x magnification. F: HSC cells with nanoparticles with 
50% PEG/30%RGD/20%NLS at a 20x magnification. 
 
Figure 22. Uptake of 10,000 g/mol conjugated nanoparticles: A: HSC cells with nanoparticles with 100% PEG at a 5x 
magnification. B: HSC cells with nanoparticles with 100% PEG at a 20x magnification. C: HSC cells with nanoparticles with 
50% PEG/50% RGD at a 5x magnification. D: HSC cells with nanoparticles with 50% PEG/50%RGD at a 20x magnification. E: 
HSC cells with nanoparticles with 50% PEG/30%RGD/20%NLS at a 5x magnification. F: HSC cells with nanoparticles with 























Growth Rate Following Cisplatin 
Exposure
The relative intensities of 
each of the different 
conjugated nanoparticles 
was analyzed. As 
expected, the PEG only 
conjugation had the 
lowest uptake intensity 
regardless of the length of 
the PEG followed by the 
uptake of nanoparticles 
with PEG and RGD with the nanoparticles with all PEG RGD and NLS having the highest uptake 
of them all. Without the presence of RGD or NLS 10,000 g/mol had the highest uptake while 5,000 
g/mol had the lowest. However, with the addition of RGD and NLS the 10,000 g/mol had the 
lowest uptake with the 5,000 g/mol had the highest uptake as concluded by an ANOVA test with 
a p value of .041.  
Changes in Cisplatin Resistant Cells 
The uptake of the conjugated nanoparticles may be decreased in cisplatin resistant human oral 
squamous cell carcinoma cells, HSC-3, as compared to non-resistant HSC-3 cells. This implication 
would lead to photothermal therapy, a therapy that is used to kill localized cancer tumors through 
heating of the nanoparticles to be less effective as less nanoparticles would be present in the cells. 
The decrease in nanoparticle uptake was not the only change that was seen with the cisplatin 
resistant cells. A noticeable morphological change was seen along with changes in growth time as 










2,000 g/mol 5,000 g/mol 10,000 g/mol
HSC Uptake Intensity
PEG PEG/RGD PEG/RGD/NLS
Figure 23. Intensity of Uptake: The intensity of the uptake of the differently conjugated 
nanoparticles was measured and analyzed. Each different conjugation was compared within 
itself and across different lengths.  
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same as previously done with the cells being exposed to small amounts of cisplatin with each new 
culture. Unlike last time however, the growth time was recorded to determine how the exposure to 
cisplatin effects the growth rate. The growth 
rates were combined into the table and graph 
below.  
Table 3. Growth Rate Following Exposure to Cisplatin The 
number of days to 85% confluence was analyzed with each 
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Figure 24. Growth Rate Following Exposure to Cisplatin (right): The growth rates were plotted against the number of exposures 
to cisplatin. It was determined that cisplatin has an exponential effect on growth rate. 
The exposure to cisplatin is seen to have an exponential effect on the growth rate of the HSC-3 
cells. As cisplatin works as a chemotherapeutic by causing DNA damage the path to which 
resistance occurs is still relatively unknown, however from these experiments it was found that 
cisplatin resistant cells experience changes to their growth cycle even from one exposure. In 
addition, the uptake of nanoparticles was studied in nonresistant and cisplatin resistant HSC-3 


























Figure 25. Cells were cultured and exposed to cisplatin for a various number of times. The cells were exposed to the same 
amount of nanoparticles before analysis via dark field imaging and ImageJ. 
The pattern that was seen in the changes in growth rate based on exposure to cisplatin is seen again 
through the uptake of nanoparticles. Though there is some changed from the first exposure to 
cisplatin, by the time the HSC-3 cells have been dosed three times the decrease in uptake is more 
drastic. As the patterns are the same for both the growth rate and the uptake of the nanoparticles 
this indicates that the two may be correlated. One explanation is that when cisplatin interacts with 
the cell and causes the resistance the surface of the HSC-3 cells is being altered. This alteration 
could be either on an intramembranous pump or on the charge of the surface itself. These changes 
would lead to different interactions between the nanoparticles leading to difference in uptake while 
simultaneously changing how long it takes for the cell to grow. More data would need to be able 
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Conclusions and Future Work 
The uptake of nanomaterial into cells can be promoted using different ligands on the nanoparticles. 
By binding ligands to the nanoparticle, it not only protected the nanoparticle but also the cell. For 
spheres the best uptake was experienced when the nanospheres were bound with PEG, RGD and 
NLS. For cubes the best uptake was experienced when the nanocubes were bound with only PEG 
and RGD. Overall the HSC-3 cells experienced more uptake than the MDA-MB-231 cells 
indicating that this combination of ligands was better suited for the HSC-3 cells as validated by 
statistical analysis. A different ratio of the current ligands or a different combination of ligands all 
together might lead to better uptake in the MDA-MB-231 cells. Since these are different cell lines 
it is expected for them to experience different uptakes as shown by the different intensities 
observed. Through additional experimentation a more precise reason for this phenomenon could 
be explained.  
 
The effects of the addition of nanoparticles on the mobility of HSC cells can be analyzed in respect 
to both its position and its velocity. The introduction of chemotherapeutic drugs often causes the 
cells to increase their velocity and scatter before the drug kills the cell as validated by statistical 
analysis. This is dangerous as the movement of cancer cells rapidly allows them to move to other 
parts of the body, thus continuing the spread of cancer. The presence of nanoparticles alone 
restricts the displacement of the HSC cells. Nanoparticles are an effective means of restricting the 
movement of the HSC cells and slowing the progress. The implications of this allow the targeting 
of cells which in turn would allow the treatment of cancer cells with reduced spreading before 
apoptosis. The introduction of cisplatin to the HSC cells causes an increase in mobility. With a 
higher concentration causing greater movement the cells are still experiencing movement great 
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enough to allow the cells to move from a central site to a previously non-cancerous site. The 
optimization of the concentration of the cisplatin should be obtained to determine the concentration 
of which an increase would cause more harm than good. Further experimentation would need to 
be run to understand the underlying effects with produce this result. While the introduction of 
cisplatin into the cells causes an increase in the mobility of the cells, coupled with the use of 
nanoparticles it may be used to effectively treat cancer without increasing the spread. The optimal 
concentration of cisplatin should be obtained from further experimentation to determine the correct 
ratios to use.  
 
The different chain lengths of the PEG along with the presence of RGD and NLS lead to 
differences in the zeta potential, radius size, and uptake intensity. With the addition of RGD all 
the different chain lengths experienced a decrease in zeta potential and the addition of NLS caused 
the zeta potential to increase. It was seen that overall the 5,000 g/mol had the highest zeta potential 
while both the 2,000 and 10,000 both remained in the neutral range for surface charge. The 5,000 
g/mol however had the highest nanoparticle uptake indicating that some surface charge might be 
beneficial to increase uptake as validated by statistical analysis. Not all the chain lengths 
experienced the same trends regarding the average radius. The 2,000 g/mol experienced an 
increase in average radius with the addition of RGD while both the 5,000 g/mol and the 10,000 
g/mol experienced a decrease. Both however experienced a larger radius that the 2,000 g/mol 
initially as expected. This indicates that the RGD may have a longer length than the 2,000 g/mol 
but shorter than the 5,000 g/mol and 10,000 g/mol. As expected, the PEG/RGD/NLS conjugations 
had the highest uptake with the PEG conjugations being the lowest. The 5,000 g/mol showed the 
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highest uptake overall indicating that there is a tradeoff between the size of the nanoparticle and 
the charge associated with it.  
 
Repeated and constant exposure to cisplatin has many effects on HCS cells. Not only does the 
exposure lead to a resistance but it also leads to growth and structural differences as indicated by 
preliminary data. This is indicative of the multiple ways in which cisplatin interacts with HSC cells 
and as such leads to a difficult resistivity to assess. As the number of prior doses of cisplatin 
increases in the presence of cisplatin alone the resistivity remains the same for all resistant cells. 
The difference in the cell viability across different cells comes into play once the nanoparticles are 
introduced. The use of nanoparticles often increases the amount of cisplatin and in turn leads to a 
lower cell viability as more cells are killed due to the cisplatin. The structural changes that 
accompany the HSC cells as their exposure to cisplatin increases leads to a reduction in the amount 
of nanoparticles that can be uptaken by the cells. The presence of nanoparticles preliminarily leads 
to a higher cell viability despite their uptake overtime slowing. With an altered nanoparticle it may 
be possible to induce more uptake into the HSC cells with more exposure and in turn lower their 
cell resistivity combating the resistance which they have built up. While it is not the cisplatin itself 
but the nanoparticle that the HSC cells are treated with in addition to the cisplatin that makes the 
difference this indicates that a difference in nanoparticles could be able to combat cisplatin 
resistance. Though it is clear throughout the study that cisplatin resistance has a clear effect on the 
uptake of the nanoparticles by the cells a more thorough understanding and analysis of the 
resistance would allow for further insights on how to overcome this barrier. Once the nanoparticles 
can overcome the resistance this would allow for an expansion of photothermal treatment to 
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